For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Human insulin
Illustration for Human insulin

THE PEPSRADAR ENCYCLOPEDIA

Human insulin

Blood-glucose regulation

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Human insulin · KEY FACTS

Content updated · how dates work

Saved peptides

What is Human insulin?

Human insulin replaces or supplements insulin activity in diabetes. Different formulations have different onset and duration, making product identity especially important.

Biological role or research focus

Blood-glucose regulation.

Different insulin products have different time courses and are not interchangeable by name alone.

Role reference: MedlinePlus · Human insulin ↗

Names you may encounter

insulin

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Glucose-regulating hormone
Main research area
Diabetes management
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Human insulin ↗

Quick answers

Is Human insulin FDA approved?
Yes. Human insulin products including Humulin R/N (BLA 018780, 018781), Novolin R/N (some sold over the counter), Myxredlin and Afrezza inhaled insulin (BLA 022472) for glycemic control in diabetes. Source ↗
Is Human insulin safe?
Essential approved hormone for diabetes; the main danger is low blood sugar, which can be severe or fatal, along with low potassium and allergic reactions. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Human insulin banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S4.4.2 Insulins and insulin-mimetics). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
DCCT (1993)Human randomized trial1,441 people with type 1 diabetes, with or without early retinopathy.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 1993

DCCT

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Population / model
1,441 people with type 1 diabetes, with or without early retinopathy.
Study design
Intensive versus conventional diabetes treatment; average follow-up 6.5 years.
Main finding
Intensive management reduced development of retinopathy by 76% in the primary-prevention group and slowed progression by 54% in the other group. Severe hypoglycemia was more frequent.
Limits & context
This tested a treatment strategy including monitoring, not one modern brand versus another. It demonstrates the tradeoff between complication reduction and hypoglycemia risk.

Source: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

48 registered studies name Human insulin as an intervention among the 100 most recently updated of 8258 search results; 21 are recruiting or under way, 13 have not started recruiting yet, 12 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603 · Eli Lilly and Company
Active, not recruitingPhase 32024-03-15320
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT07465224 · Alnylam Pharmaceuticals
Active, not recruitingPhase 22026-01-1524
The Effect of Oral Iron Supplements on Insulin and Glucose Metabolism in Overweight and Obese Women
NCT07315282 · Nicole Stoffel
RecruitingNot applicable2027-0570
Polygonatum Odoratum Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance, Inflammation and Gut Microbiota-SCFA Profiles in Men With Central Obesity
NCT07936370 · Beijing Sport University
Not yet recruitingNot applicable2026-11-01200
Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens
NCT05280184 · Nemours Children's Clinic
CompletedNot applicable2023-01-01173
Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain Injury
NCT07935278 · HealthPartners Institute
RecruitingPhase 22026-1196
The Role of Endocannabinoids in Insulin Production and Action
NCT01517100 · National Institute on Aging (NIA)
CompletedPhase 12012-01-0545
Fecal Microbiota Transplantation Intervention on Microbiota Composition and Insulin Sensitivity in Diabetes
NCT07375797 · Central Jutland Regional Hospital
CompletedNot applicable2026-02-0516

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 48 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies. ↗
Bioresources and bioprocessing · 2021 · Journal Article, Review
Read available full text ↗

Human insulin. ↗
British medical journal (Clinical research ed.) · 1986 Jan 18 · Editorial
Read available full text ↗

Expression in Escherichia coli of chemically synthesized genes for human insulin. ↗
Proceedings of the National Academy of Sciences of the United States of America · 1979 Jan · Journal Article
Read available full text ↗

Human insulin. ↗
BMJ (Clinical research ed.) · 1989 Oct 21 · Journal Article, Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Essential approved hormone for diabetes; the main danger is low blood sugar, which can be severe or fatal, along with low potassium and allergic reactions.

Human safety data: FDA label

This entry follows the label for a concentrated human insulin product (Humulin R U-500); the core risks shown apply to insulins in general. Insulin's safety profile is well established through long clinical use.

Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicines

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • During an episode of low blood sugar
  • People allergic to the insulin product or any ingredient

Interactions

  • Other diabetes drugs, ACE inhibitors, ARBs, fluoxetine, MAO inhibitors, salicylates or sulfa antibiotics: higher low blood sugar risk
  • Steroids, diuretics, estrogens, birth control pills, thyroid hormones or atypical antipsychotics: can weaken insulin's effect
  • Alcohol, beta-blockers, clonidine or lithium: may raise or lower blood sugar
  • Beta-blockers, clonidine, guanethidine or reserpine: can hide warning signs of low blood sugar
  • Thiazolidinedione diabetes drugs: fluid retention and heart failure risk

Serious risks

  • Severe low blood sugar causing seizures, loss of consciousness or death
  • Blood sugar swings when switching insulin products or regimens
  • Severe whole-body allergic reactions, including anaphylaxis
  • Low blood potassium, which can be life-threatening
  • Heart failure when combined with thiazolidinediones
  • Infection risk if pens are shared, even with a new needle

Common side effects

  • low blood sugar
  • allergic reactions
  • injection-site reactions
  • fat tissue changes at injection sites (lipodystrophy)
  • itching
  • rash

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Humulin R U-500 (insulin human) prescribing information ↗

Key precautions

Hypoglycemia can be severe or life-threatening. Product, concentration, timing, meals, illness, and activity affect risk. This page is a research reference and does not calculate or recommend insulin doses.

Source: MedlinePlus · Human insulin ↗

Regulatory status

U.S. FDA approval
Approved
Human insulin products including Humulin R/N (BLA 018780, 018781), Novolin R/N (some sold over the counter), Myxredlin and Afrezza inhaled insulin (BLA 022472) for glycemic control in diabetes. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S4.4.2 Insulins and insulin-mimetics
Insulins are named as a prohibited class at all times; a Therapeutic Use Exemption is required for medical use. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

It is central to type 1 diabetes care and used in selected people with type 2 diabetes. DCCT examined the benefits and risks of an intensive management strategy, including frequent monitoring.

Source: MedlinePlus · Human insulin ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

Insulin helps tissues take up glucose and reduces the liver’s glucose output. Formulation changes alter the time course of that activity.

Source: MedlinePlus · Human insulin ↗

Molecular structure

Human insulin: 2d molecular structure. Mature human insulin is shown. Insulin analogues and formulation additives are not included.⤢ Enlarge 2D
2D molecular structureMature human insulin is shown. Insulin analogues and formulation additives are not included.PubChem · CID 118984375 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Different insulin products have different time courses and are not interchangeable by name alone.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Is every insulin product interchangeable?

No. Time-action profiles and concentrations differ; substitution requires the correct clinical instructions.

Source: MedlinePlus · Human insulin ↗

Did DCCT identify one best insulin brand?

No. It compared management strategies, not all modern products head to head.

Source: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Human insulin

Download illustration ↓Source record ↗
Human insulin 2d molecular structure

Mature human insulin is shown. Insulin analogues and formulation additives are not included.